SARS-CoV-2 (COVID-19) ORF7a Antibody

Blue Ice

14kD

Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). SARS-CoV-2 virus proteins include structural proteins, non-structural proteins and accessory factors. The structure of SARS-CoV-2 consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. SARS-CoV-2 non-structural protein is ORF1ab that consists of 16 proteins (nsp1-nsp16), while accessory factors include ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8, ORF9b, ORF7a and ORF7a.
ORF7a plays a role as antagonist of host tetherin (BST2), disrupting its antiviral effect. It acts by binding to BST2 thereby interfering with its glycosylation. It may suppress small interfering RNA (siRNA) and may bind to host ITGAL, thereby playing a role in attachment or modulation of leukocytes (3).

Trial Size, New

SARS-CoV-2 (COVID-19) ORF7a Antibody is affinity chromatography purified via peptide column.

SARS-CoV-2 (COVID-19) ORF7a antibody is supplied in PBS containing 0.02% sodium azide.

Predicted reactivity based on immunogen sequence: SARS-CoV ORF7a: (90%); Bat coronavirus ns7a: (100%).

Polyclonal

Severe acute respiratory syndrome coronavirus 2

Optimal dilutions for each application to be determined by the researcher.